Latest BRAF Stories
Clinical Study Results Published in 2014 ASCO Annual Meeting Proceedings, a Journal of Clinical Oncology CHICAGO, June 2, 2014 /PRNewswire/ -- Trovagene, Inc.
Non-invasive detection and monitoring of actionable oncogene mutation in Erdheim-Chester disease serves as a model case for clinical utility SAN DIEGO, May 28, 2014 /PRNewswire/ --
Data demonstrate utility of non-invasive testing using urinary cell-free DNA to determine oncogene mutation status for therapy selection SAN DIEGO, May 20, 2014 /PRNewswire/ -- Trovagene,
SAN DIEGO, May 14, 2014 /PRNewswire/ -- Trovagene, Inc.
BOULDER, Colo., May 14, 2014 /PRNewswire/ -- Array BioPharma Inc.
Polaris Group Scientific Colleagues from Several University Cancer Centers Present Data at 2014 AACR Meeting in San Diego, CA SAN DIEGO, April 29, 2014 /PRNewswire/ -- Polaris Group
Three Phase 3 Trials Advancing in Patients with BRAF Melanoma, NRAS Melanoma and Low-Grade Serous Ovarian Cancer BOULDER, Colo., April 23, 2014 /PRNewswire/ -- Following the recent
QUÉBEC CITY, April 9, 2014 /PRNewswire/ - Aeterna Zentaris Inc.
Study results show correlation between mutational status and treatment response, as well as concordance between BRAF V600E mutation assay and tissue biopsy at baseline SAN DIEGO,
SAN DIEGO, April 1, 2014 /PRNewswire/ -- Trovagene, Inc.